Individuals who have bleeding disorders, thrombophilias, a history of venous thromboembolism (VTE), or who are taking anticoagulation medication for other reasons may present for abortion. Clinicians should be aware of risk factors and histories concerning for excessive bleeding and thrombotic disorders around the time of abortion. This document will focus on how to approach abortion ... Read more >

Women should be provided with evidence-based information when considering options for contraception and pregnancy management. When counseling about health conditions and available treatments, healthcare practitioners should employ strategies that encourage the incorporation of informed patient preferences into a shared decision-making process with the patient. To optimize the health of women at risk of experiencing adverse ... Read more >

Medication abortion, also referred to as medical abortion, is a safe and effective method of providing abortion. Medication abortion involves the use of medicines rather than uterine aspiration to induce an abortion. The U.S. Food and Drug Administration (FDA)-approved medication abortion regimen includes mifepristone and misoprostol. The purpose of this document is to provide updated ... Read more >

Women at high risk for maternal morbidity and mortality have unique needs for reproductive health services, including prenatal and postpartum care, contraception, and abortion. However, barriers such as restrictive state legislation, poor access to trained providers, limits in insurance coverage, and clinical challenges in assessing and communicating risk often make it difficult for these women ... Read more >

Here you can learn evidence-based ways to: Evaluate patients prior to provision of mifepristone for early abortion or miscarriage management; effectively counsel patients regarding medication abortion; and discuss criteria to determine the need for additional clinical services after use of mifepristone. CME credit is available for completing this 1 hour training.

Barriers to women’s reproductive health care access, particularly for termination of pregnancy, are increasing at the local, regional, and national levels through numerous institutional, legislative, and regulatory restrictions. Lack of access to reproductive health care has negative consequences for women’s health. Twelve women’s health care organizations affirm their support for access to comprehensive reproductive health ... Read more >

This commentary introduces the Medical Abortion Reporting of Efficacy (MARE) guidelines as a supplement to CONSORT and STROBE. The goal of the recommendations is to standardize early medical abortion efficacy reporting to facilitate comparison of outcomes between studies and to enrich the ability for data synthesis from different studies to create evidence-based guidelines. We hope ... Read more >

In the United States, more than one half of pregnancies are unintended, with 3 in 10 women having an abortion by age 45 years. In 2008, 1.2 million abortions occurred in the United States, of which 6.2% took place between 13 weeks of gestation and 15 weeks of gestation, and 4.0% took place at 16 ... Read more >

Most women undergoing first-trimester abortion are healthy. However, abortion providers also encounter women with a wide variety of medical conditions, some of which are serious and complex. When such a condition exists, consultation with the woman’s physician or a specialist can facilitate decision making regarding hospital referral and additional preparations that may be required. Medical ... Read more >

One known complication of induced abortion is upper genital tract infection, which is relatively uncommon in the current era of safe, legal abortion. Currently, rates of upper genital tract infection in the setting of legal induced abortion in the United States are generally less than 1%. Randomized controlled trials support the use of prophylactic antibiotics ... Read more >